Katherine Stueland Sells 3,639 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,639 shares of the business’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $159.28, for a total transaction of $579,619.92. Following the transaction, the chief executive officer owned 6,344 shares in the company, valued at $1,010,472.32. This represents a 36.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, October 29th, Katherine Stueland sold 2,158 shares of GeneDx stock. The stock was sold at an average price of $136.54, for a total value of $294,653.32.
• On Tuesday, September 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47.

GeneDx Stock Down 2.0%

GeneDx stock traded down $3.20 on Thursday, hitting $155.37. 273,005 shares of the stock traded hands, compared to its average volume of 886,294. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The firm has a market cap of $4.49 billion, a P/E ratio of 1,726.33 and a beta of 1.99. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The business’s fifty day simple moving average is $137.83 and its 200 day simple moving average is $112.69.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.21. The firm had revenue of $116.74 million for the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. As a group, sell-side analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently made changes to their positions in WGS. Zurcher Kantonalbank Zurich Cantonalbank grew its position in GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock valued at $399,000 after buying an additional 181 shares during the period. Jones Financial Companies Lllp increased its stake in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Quarry LP increased its stake in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after purchasing an additional 209 shares in the last quarter. Chung Wu Investment Group LLC raised its holdings in GeneDx by 8.2% in the 2nd quarter. Chung Wu Investment Group LLC now owns 3,300 shares of the company’s stock worth $305,000 after purchasing an additional 250 shares during the period. Finally, Kovack Advisors Inc. lifted its position in GeneDx by 14.3% during the third quarter. Kovack Advisors Inc. now owns 2,868 shares of the company’s stock valued at $309,000 after purchasing an additional 358 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Guggenheim restated a “buy” rating and issued a $170.00 price target (up previously from $115.00) on shares of GeneDx in a research note on Wednesday, October 29th. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Wells Fargo & Company increased their price target on shares of GeneDx from $95.00 to $140.00 and gave the company an “equal weight” rating in a report on Tuesday, November 4th. Finally, Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.22.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.